Evolving Options for HBV Therapy: Navigating the New Treatment Landscape

Would you treat or monitor a patient with low HBV DNA levels and high ALT? Here’s my take.

Tram T. Tran, MD Released: February 21, 2018

Who are the rare patients with hepatitis B infection who can benefit from peginterferon? Here’s my take.

Robert S. Brown, Jr., MD, MPH Released: May 21, 2018

When should we recommend waiting vs starting treatment in women planning to conceive and those who are already in the early or late stages of pregnancy?

Natalie H. Bzowej, MD, PhD Released: June 8, 2018

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Dynavax Technologies, Gilead Sciences, and Novartis and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Norah Terrault, MD, MPH Released: July 23, 2018

How do renal dysfunction, insurance coverage, and long-term safety concerns affect whether we should recommend TAF, TDF, or entecavir to our patients starting HBV therapy?

Jordan J. Feld, MD, MPH Released: August 17, 2018

Patients with low levels of HBV DNA are at greater risk of HCC, particularly those with cirrhosis. Read how I evaluate for causes of low-level viremia and manage patients in this situation.

Robert S. Brown, Jr., MD, MPH Released: September 24, 2018

Use this online tool to compare your management selections for your patients with HBV infection, with expert recommendations from Robert S. Brown, MD, MPH; Natalie Bzowej, MD; Jordan J. Feld, MD, MPH; Norah Terrault, MD, MPH; and Tram T. Tran, MD.

Norah Terrault, MD, MPH
Program Director Robert S. Brown, Jr., MD, MPH Natalie H. Bzowej, MD, PhD Jordan J. Feld, MD, MPH Tram T. Tran, MD Released: November 8, 2017

In this activity, Tram T. Tran, MD, presents a series of topical case studies featuring patients with chronic hepatitis B, and discusses how our expert faculty chose to manage them.

Tram T. Tran, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.8 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: December 15, 2017 Expired: No longer available for credit

In this slideset, Dr. Tram T. Tran, MD, discusses expert approaches to selecting HBV therapy in a series of cases studies involving HBV-infected patients.

Listen as expert faculty review key data and guidance on the latest treatment options for HBV infection.

Download this slideset to review key data and guidance on the latest treatment options for HBV infection.